arrow
B

Brian K. Link

University of Iowa
H指数:71
被引数:2.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

High Soluble Tumor Necrosis Factor Receptor 2 in Serum Is Associated With Inferior Overall Survival Across Major Lymphoma Subtypes

血清中高水平的可溶性肿瘤坏死因子受体2与主要淋巴瘤亚型的不良总生存期相关

2026-03-270
PRE
Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop

2024年国际滤泡性淋巴瘤科学研讨会共识建议

2025-12-050
OAAI
Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma

功能基因组学和肿瘤微环境分析揭示了套细胞淋巴瘤中的预后生物学亚型

2025-11-050
OA
Adaptation and Performance of the Self-Report-Generated Charlson Comorbidity Index in the Lymphoma Epidemiology of Outcomes (LEO) Cohort

自评生成的Charlson合并症指数在淋巴瘤结局流行病学(LEO)队列中的适应性和表现

2025-10-070
PRE
Development and Validation of a Gene Expression Signature to Predict Early Events in Patients with Follicular Lymphoma

开发和验证一种用于预测滤泡性淋巴瘤患者早期事件的基因表达谱

2025-09-220
OAAI
Genetically determined body mass index is associated with diffuse large B-cell lymphoma in polygenic and Mendelian randomization analyses

遗传决定的体质指数与多基因和孟德尔随机化分析中的弥漫性大B细胞淋巴瘤相关。

2025-09-050
OAAI
Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohorts

滤泡性淋巴瘤3B亚型具有不同的预后结局:来自前瞻性多中心MER和LEO队列的研究结果

2025-08-080
OAAI
Integrated genomics with refined cell-of-origin subtyping distinguishes subtype-specific mechanisms of treatment resistance and relapse in diffuse large B-cell lymphoma

整合基因组学与精细的细胞起源亚型划分,区分了弥漫性大B细胞淋巴瘤中特定亚型的治疗抵抗和复发机制。

2025-07-120
OAAI
Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study

R-gemox治疗复发或难治性弥漫性大b细胞淋巴瘤的疗效: 一项多中心队列研究

2025-02-070
PRE
Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature

边缘区淋巴瘤的转化:一项前瞻性队列研究及文献荟萃分析的结果

2024-11-270
OAAI
Understanding the Patient Perspective on Treatment Preferences for Follicular Lymphoma

理解患者对滤泡性淋巴瘤治疗偏好的视角

BLOOD
IF23.1
2024-11-050
PRE
Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation
2024-08-080
OAAI
Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL
2024-06-202
OAAI
Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment
2024-06-013
OAAI
Follicular lymphoma B cells exhibit heterogeneous transcriptional states with associated somatic alterations and tumor microenvironments
2024-03-015
OAAI
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes

淋巴瘤结局流行病学队列研究: 设计、基线特征和早期结局

2024-01-136
PRE
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium
2023-12-162
OAAI